THERAPEUTIC MODALITIES Archives - Page 9 of 22

Discovery, Characterization, and Manufacture of Peptide Radiopharmaceuticals

A new wave of drugs that achieves targeted delivery of radioisotopes is rapidly gaining momentum. As the discovery pipeline widens...

Armoring CAR-T Therapy with PD-1 Blockade

The efficacy of CAR-T therapy is substantially influenced by the tumor microenvironment. This is particularly evident when PD-L1 is activated...

Custom Antibody and Protein Preparation Services

WuXi AppTec provides integrated and cost-effective services for: Polyclonal and monoclonal antibodies Anti-drug antibodies (ADA), host cell protein (HCP) antibodies,...

AACR 2024 Posters: Sneak Peek

AACR 2024 Sneak Peek | Your All-In-One Guide to WuXi Biology’s Latest Advances in Cancer Research The American Association for...

PROTAC Optimization Strategies

What if a constructed PROTAC with a confirmed high-affinity warhead doesn’t work as expected? That means we need to take...

T-DXd Resistant Tumor Models with ABCG2

Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal antibodies with precise targeting and payloads, show great potential as cancer...

Rare Disease Therapeutics: Accelerating Development and Improving Access

Advances in the understanding of rare disease biology, coupled with innovative technology and therapeutic platforms, has led to progress in...

Addition of Covalent Warhead and DEL-Generated Hit Fragmentation Empower FBDD

Fragment-based drug discovery (FBDD) is one of the most well-developed approaches for projects starting from small, low-affinity compounds. At the...

DNA-Compatible Cyclizations

The recent publication in the journal Organic Letters, ‘DNA-Compatible Cyclization Reaction to Access 1,3,4-Oxadiazoles & 1,2,4-Triazoles‘ by our WuXi Biology...

Knowledge Library